SCHEMBL22301830

SCHEMBL22301830

CC/C=C\C/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)NC1CC1

nearest known ligand 0.86

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 11/20 0.86
▸ CNR1 P21554 9/20 0.86
▸ MAPT P10636 2/20 0.66
▸ ALDH1A1 P00352 2/20 0.66
▸ KMT2A Q03164 2/20 0.66
▸ MEN1 O00255 1/20 0.66
▸ HPGD P15428 1/20 0.66
▸ F7 P08709 1/20 0.49
▸ ADORA3 P0DMS8 1/20 0.49
▸ CYP19A1 P11511 1/20 0.49
▸ F3 P13726 1/20 0.49
▸ RXRA P19793 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ PPARG P37231 1/20 0.49
▸ PPARD Q03181 1/20 0.49
▸ PPARA Q07869 1/20 0.49
▸ OXER1 Q8TDS5 1/20 0.49
▸ TRPV1 Q8NER1 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20840229 0.92 CNR2 (1.00) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL12555962 0.89 ALDH1A1 (0.81) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL12555932 0.88 MAPT (0.71) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL18885368 0.83 ALDH1A1 (0.70) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL652290 0.83 MAPT (0.81) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL652501 0.83 MAPT (0.81) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL654221 0.83 MAPT (0.81) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL12961411 0.83 MAPT (0.81) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL4982180 0.80 MEN1 (1.00) CNR2CNR1MAPTALDH1A1KMT2A
SCHEMBL6517985 0.80 MEN1 (1.00) CNR2CNR1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247777-A1 DERIVATIVES OF EPA ENDOCANNABINOID EPOXIDES AS ANTI-INFLAMMATORY, ANTI-CANCEROUS, ANTI-ANGIOGENC AND ANTIPLATELET AGGREGATION COMPOUNDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2020-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247777-A1 DERIVATIVES OF EPA ENDOCANNABINOID EPOXIDES AS ANTI-INFLAMMATORY, ANTI-CANCEROUS, ANTI-ANGIOGENC AND ANTIPLATELET AGGREGATION COMPOUNDS PTGES, PTGIS, PTGER1 CNR2 26/4885CNR1 40/4885MAPT 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback